Association of SOD1 rs36232792 with opioid use disorder and a novel PCR-RFLP method for SOD2 rs5746136.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-04-16 DOI:10.1080/14622416.2025.2490467

Seval Küçükparmaksız, Dilek Kaya Akyüzlü, Selin Özkan Kotiloğlu, Mustafa Danışman

{"title":"Association of SOD1 rs36232792 with opioid use disorder and a novel PCR-RFLP method for SOD2 rs5746136.","authors":"Seval Küçükparmaksız, Dilek Kaya Akyüzlü, Selin Özkan Kotiloğlu, Mustafa Danışman","doi":"10.1080/14622416.2025.2490467","DOIUrl":null,"url":null,"abstract":"Aim: The aim of this study is to find out the effect of SOD1 rs36232792 and SOD2 rs5746136 on the risk of opioid use disorder (OUD).Methods: Individuals with OUD (n = 101) and controls (n = 104) were included. SOD1 rs36232792 was genotyped by PCR. A novel PCR-RFLP method for SOD2 rs5746136 was optimized.Results: A significant difference was observed between individuals with OUD and controls in view of the frequency of 'Ins/Del+Del/Del' genotypes of the SOD1 rs36232792 (p = 0.049), but not for SOD2 rs5746136 (p = 0.254). The intensity of anxiety and depressive symptoms was significantly higher in individuals with OUD compared to controls (p = 0.001).Conclusion: The SOD1 rs36232792 polymorphism could contribute to the risk of OUD in a Turkish population. A novel PCR-RFLP method for SOD2 rs5746136 confirmed by sequencing can be used in a research laboratory without advanced equipment.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"1-11"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2490467","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The aim of this study is to find out the effect of SOD1 rs36232792 and SOD2 rs5746136 on the risk of opioid use disorder (OUD).

Methods: Individuals with OUD (n = 101) and controls (n = 104) were included. SOD1 rs36232792 was genotyped by PCR. A novel PCR-RFLP method for SOD2 rs5746136 was optimized.

Results: A significant difference was observed between individuals with OUD and controls in view of the frequency of 'Ins/Del+Del/Del' genotypes of the SOD1 rs36232792 (p = 0.049), but not for SOD2 rs5746136 (p = 0.254). The intensity of anxiety and depressive symptoms was significantly higher in individuals with OUD compared to controls (p = 0.001).

Conclusion: The SOD1 rs36232792 polymorphism could contribute to the risk of OUD in a Turkish population. A novel PCR-RFLP method for SOD2 rs5746136 confirmed by sequencing can be used in a research laboratory without advanced equipment.

查看原文本刊更多论文

SOD1 rs36232792与阿片类药物使用障碍的关联及SOD2 rss5746136的新型PCR-RFLP方法

目的：本研究旨在探讨SOD1 rs36232792和SOD2 rss5746136对阿片类药物使用障碍（OUD）风险的影响。方法：纳入OUD患者（n = 101）和对照组（n = 104）。用PCR方法对SOD1 rs36232792进行基因分型。优化了SOD2 rs5746136的PCR-RFLP检测方法。结果：在SOD1 rs36232792的“Ins/Del+Del/Del”基因型频率上，OUD个体与对照组有显著差异（p = 0.049），而SOD2 rss5746136无显著差异（p = 0.254）。与对照组相比，OUD患者的焦虑和抑郁症状强度显著升高（p = 0.001）。结论：SOD1 rs36232792多态性可能与土耳其人群的OUD风险有关。经测序确认的新型SOD2 rs5746136 PCR-RFLP方法可以在没有先进设备的研究实验室中使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.